Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting


CAN A., Ulus A. T., ÇINAR Ö., TOPAL ÇELİKKAN F., Simsek E., AKYOL M., ...Daha Fazla

STEM CELL REVIEWS AND REPORTS, cilt.11, sa.5, ss.752-760, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1007/s12015-015-9601-0
  • Dergi Adı: STEM CELL REVIEWS AND REPORTS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.752-760
  • Anahtar Kelimeler: Umbilical cord MSC, Bone marrow MNC, Ischemic cardiomyopathy, Regenerative medicine, Stem cell therapy, Clinical trial, STEM-CELL, BONE-MARROW, TRANSCORONARY TRANSPLANTATION, INTRACORONARY TRANSPLANTATION, IMMUNE PROPERTIES, PROGENITOR CELLS, HEART-FAILURE, IN-VIVO, THERAPY, SAFETY
  • Ankara Üniversitesi Adresli: Evet

Özet

Mesenchymal stem cells (MSCs), which may be obtained from the bone marrow, have been studied for more than a decade in the setting of coronary artery disease (CAD). Adipose tissue-derived MSCs have recently come into focus and are being tested in a series of clinical trials. MSC-like cells have also been derived from a variety of sources, including umbilical cord stroma, or HUC-MSCs. The HUC-HEART trail (ClinicalTrials. gov Identifier: NCT02323477) is a phase 1/2, controlled, multicenter, randomized clinical study of the intramyocardial delivery of allogeneic HUC-MSCs in patients with chronic ischemic cardiomyopathy. A total of 79 patients (ages 30-80) with left ventricle ejection fractions ranging between 25 and 45 % will be randomized in a 2:1:1 pattern in order to receive an intramyocardial injection of either HUC-MSCs or autologous bone marrow-derived mononuclear cells (BM-MNCs) in combination with coronary arterial bypass grafting (CABG) surgery. The control group of patients will receive no cells and undergo CABG alone. Human HUCMSCs will be isolated, propagated and banked in accordance with a cGMP protocol, whereas the autologous BM-MNCs will be isolated via aspiration from the iliac crest and subsequently process in a closed-circuit cell purification system shortly before cell transplantation. The cell injections will be implemented in 10 peri-infarct areas. Baseline and post-transplantation outcome measures will be primarily utilized to test both the safety and the efficacy of the administered cells for up to 12 months.